The global market for hydroxychloroquine sulfate tablets is expected to grow at a significant CAGR during the forecast period (2021-2027). Hydroxychloroquine is a safer chloroquine derivative. Although the medication is ineffective for chloroquine-resistant malaria, hydroxychloroquine is an immunosuppressive and anti-parasite therapy used to treat or prevent malaria. When other medicines fail or cannot be used to treat autoimmune disorders including systemic and discoid lupus erythematosus and rheumatoid arthritis (acute and severe), hydroxychloroquine is recommended. A variety of viruses can be treated using broad-spectrum hydroxychloroquine Sulfate tablets. According to the China's Ministry of Science and Technology, hydroxychloroquine is one of the medicines that has shown to be effective in preventing coronavirus infection in the early clinical trials.

Increased malaria incidence and increased need for effective and safe treatment are expected to drive up demand. Due to its effectiveness against a wide range of parasite types, hydroxychloroquine Sulfate tablets are frequently employed in the treatment of malaria. The incidence of malaria in Africa reached 210,000 cases in 2018, which is expected to increase demand for hydroxychloroquine Sulfate tablets. Furthermore, the market for hydroxychloroquine Sulfate is expected to grow due to its easy availability, low cost, and ability to decrease platelet loss.

Furthermore, rising occurrences of skin lesions and psoriasis as a result of rising pollution levels and poor diets are expected to drive up demand. Due to its antibacterial properties and capacity to inhibit aberrant skin cell development, hydroxychloroquine Sulfate is commonly recommended to treat skin disorders. It is water soluble and may be utilized in paediatric medicine, thus demand is expected to rise. The hydroxychloroquine Sulfate market is expected to grow due to increased awareness of dermatological aspects of healthcare and increased desire for quick-acting treatments.

The launch of generic equivalents, as well as a strong clinical pipeline, are expected to drive market growth. Zydus Cadila and Ipca Labs, for instance, will have backward integrated HCQ manufacturing capability in April 2020, with the goal of increasing production capacity by 5-6 times to 70 MT per month, to meet the inceasing demand for treatment choices for people living with target illnesses..

The US FDA gave final clearance to Lupin's Hydroxychloroquine Sulfate Tablets USP, 200 mg in 2018, allowing it to market a generic version of Concordia Pharmaceuticals, Inc.'s Plaquenil Tablets, 200 mg.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Product – 100 mg, 200 mg

o By Application – Hospital Pharmacy, Retail Pharmacy

o By Disease – Malaria, Arthritis, Skin Lesions, Lupus, COVID 19

    • Competitive Landscape: Teva Pharmaceutical Industries Ltd., Mylan, Novartis, Hikma Pharmaceuticals, Ipca Laboratories, Shanghai Pharmaceuticals Holding Co. Ltd., Sanofi, Taj Pharmaceuticals Limited, Cinkate Corporation and Concordia Healthcare, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Hydroxychloroquine Sulfate Tablets Market Report 

By Product

    • 100 mg

    • 200 mg

By Application

    • Hospital Pharmacy

    • Retail Pharmacy

By Disease

    • Malaria

    • Arthritis

    • Skin Lesions

    • Lupus

    • COVID-19

By Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa